HENGRUI PHARMA(01276),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

01276 HENGRUI PHARMA

Trading 08-27 15:31:48

48.060

+1.340

+2.87%

High48.280	Low45.880	Vol11.05M
Open46.920	D1 Closing46.720	Amplitude5.14%
Mkt Cap318.97B	Tradable Cap12.40B	Total Shares6.64B
T/O520.32M	T/O Rate4.28%	Tradable Shares258.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"01276","market":"HK","secType":"STK","nameCN":"HENGRUI PHARMA","latestPrice":48.06,"timestamp":1787815901707,"preClose":46.72,"halted":0,"volume":11048631,"delay":0,"changeRate":0.02868150684931514,"floatShares":258000000,"shares":6637000000,"eps":1.3765710881527586,"marketStatus":"Trading","change":1.34,"latestTime":"08-27 15:31:48","open":46.92,"high":48.28,"low":45.88,"amount":520319740,"amplitude":0.05137,"askPrice":48.08,"askSize":16400,"bidPrice":48.06,"bidSize":3400,"shortable":3,"etf":0,"ttmEps":1.3575440759088844,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1787818200000},"marketStatusCode":2,"adr":0,"listingDate":1747929600000,"exchange":"SEHK","adjPreClose":46.72,"dividendRate":0.004855,"openAndCloseTimeList":[[1787794200000,1787803200000],[1787806800000,1787817600000]],"volumeRatio":0.887541,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"600276","market":"SH","secType":"STK","nameCN":"Jiangsu Hengrui Pharmaceuticals Co.,Ltd.","latestPrice":47.61,"timestamp":1787814000000,"preClose":46.74,"halted":0,"volume":77849500,"delay":0,"premium":"-13.47"}},"requestUrl":"/m/hq/s/01276","defaultTab":"news","newsList":[{"id":"1165601808","title":"Movement Alert｜HENGRUI PHARMA Rises 3.04% in Regular Trading, GIC Private Limited Consecutively Increases Stake to 17.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=1165601808","media":"Market Focus","labels":["shareholding"],"top":1,"itemType":null,"share":"https://ttm.financial/m/news/1165601808?lang=en_us&edition=fundamental","pubTime":"2026-08-27 15:02","pubTimestamp":1787814123,"startTime":"0","endTime":"0","summary":"On August 27, HENGRUI PHARMA rose 3.04% in regular trading, trading at 48.12 HKD/share, with turnover of HKD 478 million.On the news front, Hong Kong Exchange disclosures revealed that Singapore...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"GIC Boosts Hengrui Pharma Stake to 17.19% as Shares Rise","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106227619","title":"Singapore Sovereign Fund Boosts Stake in Chinese Drugmaker with HK$185 Million Share Purchase","url":"https://stock-news.laohu8.com/highlight/detail?id=1106227619","media":"Deep News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1106227619?lang=en_us&edition=fundamental","pubTime":"2026-08-27 08:10","pubTimestamp":1787789429,"startTime":"0","endTime":"0","summary":"Hong Kong stock exchange disclosures have revealed a notable transaction involving a major global institutional investor and a leading Chinese pharmaceutical company.On August 21, GIC Private...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1820825898.SGD","LU1997245177.USD","01276","LU0405327494.USD","LU2580892789.USD","LU1255011170.USD","BK0188","LU1655091616.SGD","BK4104","LU2097828631.EUR","BK0196","LU2097828805.USD","LU2097828557.USD","BK0012","600276","LU2289578879.USD","LU1969619763.USD","LU0359201885.HKD","LU1146622755.USD","LU2495084118.USD","BK0239","BK0060","BK1191","LU0359201612.USD","LU1064131003.USD","LU1064130708.USD","LU2543165471.USD","LU1023057109.AUD","LU1997244956.HKD","GIC","LU1997245094.SGD","LU2097828474.EUR","LU2580892862.HKD","LU2328871848.SGD","LU1781817850.SGD","EWH","LU0359202008.SGD","LU2488822045.USD","LU1580142542.USD","BK0028","LU0405327148.USD","LU2097828714.EUR","LU2148510915.USD","LU1328615791.USD","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662790837","title":"JPMorgan Chase & Co.'S Short Position in H-Shares of Jiangsu Hengrui Pharmaceuticals Co., Ltd. Increases to 3.72% on August 21 from 2.57% - HKEX","url":"https://stock-news.laohu8.com/highlight/detail?id=2662790837","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662790837?lang=en_us&edition=fundamental","pubTime":"2026-08-26 18:28","pubTimestamp":1787740118,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nFWN44N0FH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0359202008.SGD","LU2097828557.USD","LU2580892789.USD","LU0405327148.USD","LU1997244956.HKD","LU2328871848.SGD","LU2148510915.USD","LU1255011170.USD","LU2580892862.HKD","LU2097828474.EUR","LU1997245094.SGD","LU1781817850.SGD","LU1064131003.USD","LU1328615791.USD","BK0028","LU1969619763.USD","LU2097828714.EUR","LU2495084118.USD","LU1023057109.AUD","LU2097828631.EUR","LU2097828805.USD","LU1064130708.USD","BK0012","LU1580142542.USD","BK0183","LU2488822045.USD","LU1146622755.USD","LU0359201612.USD","BK0060","01276","LU0359201885.HKD","LU1997245177.USD","BK0239","BK0196","LU1655091616.SGD","LU2289578879.USD","LU0405327494.USD","BK0188","BK1191","LU1820825898.SGD","LU2543165471.USD","600276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100671669","title":"Singapore's GIC Boosts Stake in Hengrui Pharma With HK$185 Million Share Purchase","url":"https://stock-news.laohu8.com/highlight/detail?id=1100671669","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100671669?lang=en_us&edition=fundamental","pubTime":"2026-08-25 19:30","pubTimestamp":1787657435,"startTime":"0","endTime":"0","summary":"Hong Kong exchange filings reveal that on August 20, GIC Private Limited acquired an additional 3.6586 million shares of HENGRUI PHARMA (01276) at an average price of HK$50.5655 per share, bringing...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2495084118.USD","LU0359201885.HKD","BK4104","BK0028","LU2543165471.USD","LU0405327148.USD","LU2289578879.USD","LU2580892789.USD","LU1328615791.USD","LU2148510915.USD","BK0183","LU1781817850.SGD","LU2097828474.EUR","LU1969619763.USD","LU2097828805.USD","GIC","LU0359202008.SGD","LU2097828631.EUR","LU1580142542.USD","LU1023057109.AUD","BK0060","LU0405327494.USD","BK1191","BK0196","LU1997245094.SGD","LU2097828714.EUR","600276","LU1997244956.HKD","LU1064130708.USD","BK0239","LU1997245177.USD","LU1064131003.USD","LU2097828557.USD","LU1655091616.SGD","LU2580892862.HKD","LU1146622755.USD","BK0188","BK0012","01276","LU0359201612.USD","LU2328871848.SGD","LU1820825898.SGD","EWH","LU1255011170.USD","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143746816","title":"HENGRUI PHARMA: GIC Private Limited Acquires Shares, Long Position Rises to 15.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=1143746816","media":"HK Disclosure","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1143746816?lang=en_us&edition=fundamental","pubTime":"2026-08-25 17:16","pubTimestamp":1787649406,"startTime":"0","endTime":"0","summary":"GIC Private Limited bought 3.66 million shares of HENGRUI PHARMA at an average of HKD 50.5655 per share on August 20, 2026, involving about HKD 185.00 million.Prior to the acquisition, GIC Private...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"a44b570a4bc942c79569e09a943adc8c","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662678835","title":"Chinese Drug Regulator Accepts Hengrui Pharma's Drug Marketing Application for HRG2010 Capsules","url":"https://stock-news.laohu8.com/highlight/detail?id=2662678835","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662678835?lang=en_us&edition=fundamental","pubTime":"2026-08-25 10:43","pubTimestamp":1787625833,"startTime":"0","endTime":"0","summary":"China's National Medical Products Administration accepted Jiangsu Hengrui Pharmaceuticals' (SHA:600276, HKG:1276) drug marketing authorization application for HRG2010 capsules, according to a Shanghai bourse filing on Tuesday.The drug is used for the treatment of Parkinson's disease.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1023057109.AUD","LU0359202008.SGD","01276","LU0359201885.HKD","LU0359201612.USD","LU2543165471.USD","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156894355","title":"HENGRUI PHARMA's HRG2010 Capsule Marketing Application Accepted by NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=1156894355","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156894355?lang=en_us&edition=fundamental","pubTime":"2026-08-24 22:24","pubTimestamp":1787581455,"startTime":"0","endTime":"0","summary":"HENGRUI PHARMA (01276) has announced that its marketing authorization application for the HRG2010 capsule has been formally accepted by China's National Medical Products Administration (NMPA),...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0359202008.SGD","LU2097828557.USD","LU2580892789.USD","LU0405327148.USD","LU1997244956.HKD","LU2328871848.SGD","LU2148510915.USD","LU1255011170.USD","LU2580892862.HKD","LU2097828474.EUR","LU1997245094.SGD","LU1781817850.SGD","LU1064131003.USD","LU1328615791.USD","BK0028","LU1969619763.USD","LU2097828714.EUR","LU2495084118.USD","LU1023057109.AUD","LU2097828631.EUR","LU2097828805.USD","LU1064130708.USD","BK0012","LU1580142542.USD","BK0183","LU2488822045.USD","LU1146622755.USD","LU0359201612.USD","BK0060","01276","LU0359201885.HKD","LU1997245177.USD","BK0239","BK0196","LU1655091616.SGD","LU2289578879.USD","LU0405327494.USD","BK0188","BK1191","LU1820825898.SGD","LU2543165471.USD","600276","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661446273","title":"Nomura Adjusts Jiangsu Hengrui Pharmaceuticals' Price Target to HK$82.18 From HK$87.49, Keeps at Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2661446273","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661446273?lang=en_us&edition=fundamental","pubTime":"2026-08-24 19:13","pubTimestamp":1787570024,"startTime":"0","endTime":"0","summary":"Jiangsu Hengrui Pharmaceuticals (HKG:1276) has an average rating of overweight and mean price target of HK$81.15, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and eco","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0359201885.HKD","LU1023057109.AUD","LU0359201612.USD","01276","LU0359202008.SGD","LU2543165471.USD","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125046383","title":"Hengrui Pharma's Half-Year Report: Heavy Spending Fails to Drive Growth as Former Sector Leader Struggles with Revenue Without Profit Expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=1125046383","media":"Deep News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1125046383?lang=en_us&edition=fundamental","pubTime":"2026-08-24 15:46","pubTimestamp":1787557589,"startTime":"0","endTime":"0","summary":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SH: 600276) unveiled its half-year financial report in August 2026, and the mid-year scorecard, which had generated considerable market anticipation, fell...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2495084118.USD","LU0359201885.HKD","BK0028","LU2543165471.USD","LU0405327148.USD","LU2289578879.USD","LU2580892789.USD","LU1328615791.USD","LU2148510915.USD","BK0183","LU1781817850.SGD","LU2097828474.EUR","LU1969619763.USD","LU2097828805.USD","BK1161","BK1515","LU0359202008.SGD","BK1574","LU2097828631.EUR","LU1580142542.USD","LU1023057109.AUD","BK0060","LU0405327494.USD","BK1191","BK0196","LU1997245094.SGD","LU2097828714.EUR","09939","600276","LU1997244956.HKD","LU1064130708.USD","BK0239","LU1997245177.USD","LU1064131003.USD","LU2097828557.USD","LU1655091616.SGD","LU2580892862.HKD","LU1146622755.USD","BK0188","BK0012","01276","LU0359201612.USD","LU2328871848.SGD","LU1820825898.SGD","159938","LU1255011170.USD","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102739299","title":"Movement Alert｜HENGRUI PHARMA Falls 3.03% in Regular Trading, BOCOM International Cuts Target Price Citing Continued Pressure on Legacy Products","url":"https://stock-news.laohu8.com/highlight/detail?id=1102739299","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1102739299?lang=en_us&edition=fundamental","pubTime":"2026-08-24 10:41","pubTimestamp":1787539319,"startTime":"0","endTime":"0","summary":"On August 24, HENGRUI PHARMA fell 3.03% in regular trading, trading at HKD 46.74/share, with turnover of HKD 327 million. The decline was triggered by BOCOM International issuing a research note on...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"BOCOM International Cuts Hengrui Pharma Target Price","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157060014","title":"Hengrui Pharma's Growth Architecture Shifts: Second Growth Engine Accelerates as Global Valuation Framework Expands","url":"https://stock-news.laohu8.com/highlight/detail?id=1157060014","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1157060014?lang=en_us&edition=fundamental","pubTime":"2026-08-23 21:06","pubTimestamp":1787490393,"startTime":"0","endTime":"0","summary":"On August 19, Hengrui Pharma (01276) delivered a resilient first-half earnings report. During the period, the company recorded operating revenue of RMB 15.456 billion, with net profit attributable to...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1997244956.HKD","LU2580892862.HKD","LU0405327148.USD","LU1969619763.USD","LU1997245177.USD","LU2097828631.EUR","LU1146622755.USD","LU2328871848.SGD","LU1064131003.USD","LU1064130708.USD","LU2097828805.USD","LU1997245094.SGD","LU2148510915.USD","LU1781817850.SGD","BK0188","LU1820825898.SGD","LU0359201612.USD","BK1191","LU1023057109.AUD","LU1255011170.USD","LU1328615791.USD","LU2097828557.USD","BK0012","BK0183","600276","LU2097828714.EUR","LU2580892789.USD","LU1580142542.USD","LU0359201885.HKD","LU2495084118.USD","LU2543165471.USD","LU0405327494.USD","LU1655091616.SGD","LU2289578879.USD","LU2488822045.USD","BK0196","LU2097828474.EUR","LU0359202008.SGD","01276","BK0239","BK0028","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661212256","title":"Hengrui Pharma Gets Nod to Trial SHR-8203 Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=2661212256","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661212256?lang=en_us&edition=fundamental","pubTime":"2026-08-21 10:08","pubTimestamp":1787278105,"startTime":"0","endTime":"0","summary":"Jiangsu Hengrui Pharmaceuticals  received approval from China's National Medical Products Administration for the clinical trial of SHR-8203 injection, according to a Shanghai bourse filing on Friday.The drug will be tested as a monotherapy for advanced solid tumors.The Chinese pharmaceutical company's Shanghai shares dropped 3% during the morning trade.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["01276","LU0359201612.USD","LU1023057109.AUD","LU2543165471.USD","BK1191","LU0359202008.SGD","LU0359201885.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661256285","title":"Hengrui Pharma Unit Gets China Nod for Lupus Drug Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2661256285","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661256285?lang=en_us&edition=fundamental","pubTime":"2026-08-21 10:05","pubTimestamp":1787277919,"startTime":"0","endTime":"0","summary":"Jiangsu Hengrui Pharmaceuticals  (SHA:600276) unit Guangdong Hengrui Medicine obtained approval from China's drug regulator to begin clinical trials for SHR-7012 injection.SHR-7012 targets cutaneous lupus erythematosus, according to a Thursday aftermarket filing.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1023057109.AUD","BK1191","LU0359201885.HKD","01276","LU0359201612.USD","LU2543165471.USD","LU0359202008.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175051703","title":"Movement Alert｜HENGRUI PHARMA Declines 3.18% in Regular Trading, Extending Sell-Off on Weak H1 Earnings Quality","url":"https://stock-news.laohu8.com/highlight/detail?id=1175051703","media":"Market Focus","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1175051703?lang=en_us&edition=fundamental","pubTime":"2026-08-21 09:42","pubTimestamp":1787276522,"startTime":"0","endTime":"0","summary":"On August 21, HENGRUI PHARMA declined 3.18% in regular trading, trading at 47.66 HKD/share with turnover of approximately 109 million HKD, extending the prior session's 8.55% selloff.The decline...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Hengrui Pharma Extends Decline on Weak Cash Flow and Core Profit","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660282560","title":"Hengrui Pharmaceuticals Unit Gets China Marketing Nod for Paroxysmal Nocturnal Hemoglobinuria Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2660282560","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660282560?lang=en_us&edition=fundamental","pubTime":"2026-08-20 20:48","pubTimestamp":1787230129,"startTime":"0","endTime":"0","summary":"Jiangsu Hengrui Pharmaceuticals  unit Chengdu Suncadia Medicine obtained marketing approval for its Licancopan Fumarate Capsules from China's National Medical Products Administration.The approved indication is for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria  who have not previously received complement inhibitor therapy, according to a Thursday bourse filing.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1191","LU0359201612.USD","01276","LU0359201885.HKD","LU1023057109.AUD","LU2543165471.USD","LU0359202008.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660285347","title":"Jiangsu Hengrui Pharmaceuticals- Nmpa Notice Approving Developed Class 1 Innovative Drug Licancopan Fumarate (Hrs-5965) Capsules for Marketing","url":"https://stock-news.laohu8.com/highlight/detail?id=2660285347","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660285347?lang=en_us&edition=fundamental","pubTime":"2026-08-20 18:31","pubTimestamp":1787221884,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260820:nFWN44H0I8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1064130708.USD","BK0028","BK0196","LU2495084118.USD","LU2543165471.USD","LU1655091616.SGD","LU0405327494.USD","BK0060","BK0183","LU1781817850.SGD","LU1997245094.SGD","01276","LU2328871848.SGD","LU2097828474.EUR","LU2580892789.USD","LU0359201885.HKD","LU0405327148.USD","LU0359202008.SGD","BK0012","600276","BK0239","LU2097828805.USD","LU1580142542.USD","LU2289578879.USD","LU1328615791.USD","LU1820825898.SGD","LU1997244956.HKD","LU1997245177.USD","LU2097828631.EUR","LU1023057109.AUD","LU1064131003.USD","LU0359201612.USD","LU2148510915.USD","LU2097828557.USD","LU1146622755.USD","LU2580892862.HKD","LU2488822045.USD","LU1969619763.USD","BK0188","LU1255011170.USD","BK1191","LU2097828714.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130698825","title":"HENGRUI PHARMA (01276) Gets Clinical Trial Approval for SHR-7012 Injection Targeting Cutaneous Lupus Erythematosus","url":"https://stock-news.laohu8.com/highlight/detail?id=1130698825","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1130698825?lang=en_us&edition=fundamental","pubTime":"2026-08-20 18:26","pubTimestamp":1787221594,"startTime":"0","endTime":"0","summary":"HENGRUI PHARMA (01276) has announced that its subsidiary, Guangdong Hengrui Pharmaceuticals Co., Ltd., has received the Drug Clinical Trial Approval Notice issued by the National Medical Products...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1064131003.USD","LU0405327148.USD","BK0060","LU2148510915.USD","BK0028","BK0188","LU1969619763.USD","LU2097828714.EUR","LU1781817850.SGD","LU2580892862.HKD","01276","LU0405327494.USD","LU2328871848.SGD","MDTX","LU1655091616.SGD","600276","BK0196","BMED","LU0359201612.USD","LU1997244956.HKD","LU1997245094.SGD","LU1023057109.AUD","BK0183","LU2580892789.USD","BK0012","LU2495084118.USD","LU1820825898.SGD","LU1064130708.USD","BK1191","PSYK","LU1146622755.USD","LU2097828557.USD","LU0359202008.SGD","LU1255011170.USD","LU1997245177.USD","LU2097828805.USD","LU1328615791.USD","BK0239","LU2289578879.USD","LU2488822045.USD","LU0359201885.HKD","IBBQ","LU2097828474.EUR","LU1580142542.USD","LU2543165471.USD","IBBJ","LU2097828631.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660118408","title":"Jiangsu Hengrui Hong Kong Shares Hit Record Low on Quarterly Profit Miss","url":"https://stock-news.laohu8.com/highlight/detail?id=2660118408","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660118408?lang=en_us&edition=fundamental","pubTime":"2026-08-20 12:20","pubTimestamp":1787199653,"startTime":"0","endTime":"0","summary":"BUZZ-Jiangsu Hengrui Hong Kong shares hit record low on quarterly profit miss** Hong Kong shares of Jiangsu Hengrui Pharmaceuticals1276.HKdrop 11.2% to HK$48.8, record low since debut in May 2025** St","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260820:nL1N44H03J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0012","BK0060","LU1997244956.HKD","LU2488822045.USD","BK1191","LU0359201612.USD","LU1997245094.SGD","LU1023057109.AUD","LU1997245177.USD","BK0183","LU2097828714.EUR","BK0239","LU1146622755.USD","LU2097828631.EUR","LU2097828557.USD","LU0405327148.USD","01276","BK0028","LU1969619763.USD","LU0359201885.HKD","LU1255011170.USD","LU1781817850.SGD","LU2328871848.SGD","LU2289578879.USD","LU2543165471.USD","BK0196","LU1580142542.USD","BK0188","LU2148510915.USD","LU1064131003.USD","LU2580892862.HKD","LU2580892789.USD","LU0359202008.SGD","600276","LU1820825898.SGD","LU2097828474.EUR","LU2495084118.USD","LU1328615791.USD","LU2097828805.USD","LU1064130708.USD","LU0405327494.USD","LU1655091616.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148990473","title":"Movement Alert｜HENGRUI PHARMA Falls 8.55% in Regular Trading, H1 Revenue Declines as Core Profit Drops 12.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=1148990473","media":"Market Focus","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1148990473?lang=en_us&edition=fundamental","pubTime":"2026-08-20 09:33","pubTimestamp":1787189623,"startTime":"0","endTime":"0","summary":"On August 20, HENGRUI PHARMA fell 8.55% in regular trading, trading at HK$50.85/share, with turnover of HK$109 million. The selloff was triggered by the company's disappointing first-half earnings...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"HENGRUI PHARMA Falls as H1 Revenue Declines as Core Profit Drops 12.7%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171904948","title":"Hengrui Pharma Announces Resignation of Joint Company Secretary Liu Xiaohan","url":"https://stock-news.laohu8.com/highlight/detail?id=1171904948","media":"Bulletin Express","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1171904948?lang=en_us&edition=fundamental","pubTime":"2026-08-19 22:29","pubTimestamp":1787149741,"startTime":"0","endTime":"0","summary":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (“Hengrui Pharma”) disclosed that Ms. Liu Xiaohan resigned from her position as joint company secretary, effective 19 August 2026. According to the board,...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.hrs.com.cn","stockEarnings":[{"period":"1week","weight":-0.1498},{"period":"1month","weight":-0.1811},{"period":"3month","weight":-0.1973},{"period":"6month","weight":-0.295},{"period":"1year","weight":-0.3811},{"period":"ytd","weight":-0.342}],"compareEarnings":[{"period":"1week","weight":0.0062},{"period":"1month","weight":0.0177},{"period":"3month","weight":0.0259},{"period":"6month","weight":-0.0367},{"period":"1year","weight":0.005},{"period":"ytd","weight":0.0009}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Jiangsu Hengrui Pharmaceuticals Co Ltd is a China-based company mainly engaged in the research, development, production and sales of drugs. The Company focuses on the field of oncology, covering kinase inhibitors, antibody-drug conjugates (ADCs), tumor immunity, hormone receptor regulation, deoxyribonucleic acid (DNA) repair and epigenetics, supportive care and other research areas. The Company's products include anti-tumor, analgesic anesthesia and contrast agents, which are used in autoimmune diseases, metabolic diseases, cardiovascular diseases, infectious diseases, respiratory diseases, blood diseases, pain management, neurological diseases, ophthalmology, nephrology and other fields. The Company mainly conducts its businesses in domestic and foreign markets.","exchange":"SEHK","name":"HENGRUI PHARMA","nameEN":"HENGRUI PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"HENGRUI PHARMA(01276),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest HENGRUI PHARMA(01276) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"HENGRUI PHARMA,01276,HENGRUI PHARMA股票,HENGRUI PHARMA股票老虎,HENGRUI PHARMA股票老虎国际,HENGRUI PHARMA行情,HENGRUI PHARMA股票行情,HENGRUI PHARMA股价,HENGRUI PHARMA股市,HENGRUI PHARMA股票价格,HENGRUI PHARMA股票交易,HENGRUI PHARMA股票购买,HENGRUI PHARMA股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"HENGRUI PHARMA(01276),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest HENGRUI PHARMA(01276) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}